GBT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GBT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Global Blood Therapeutics's enterprise value is $4,762.7 Mil. Global Blood Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-287.9 Mil. Therefore, Global Blood Therapeutics's EV-to-EBITDA for today is -16.54.
The historical rank and industry rank for Global Blood Therapeutics's EV-to-EBITDA or its related term are showing as below:
During the past 9 years, the highest EV-to-EBITDA of Global Blood Therapeutics was -5.65. The lowest was -17.95. And the median was -10.00.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-05), Global Blood Therapeutics's stock price is $68.49. Global Blood Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-5.010. Therefore, Global Blood Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Global Blood Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Blood Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | ||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -12.76 | -10.67 | -17.03 | -10.37 | -6.70 |
Global Blood Therapeutics Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -8.09 | -5.85 | -6.70 | -8.42 | -7.96 |
For the Biotechnology subindustry, Global Blood Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Global Blood Therapeutics's EV-to-EBITDA falls into.
Global Blood Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 4762.671 | / | -287.937 | |
= | -16.54 |
Global Blood Therapeutics's current Enterprise Value is $4,762.7 Mil.
Global Blood Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-287.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Blood Therapeutics (NAS:GBT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Global Blood Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 68.49 | / | -5.010 | |
= | At Loss |
Global Blood Therapeutics's share price for today is $68.49.
Global Blood Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Global Blood Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey S Farrow | officer: Chief Financial Officer | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Nazila Habibizad | officer: See Remarks | C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080 |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Philip A. Pizzo | director | ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Carrie Krehlik | officer: Chief Human Resources Officer | 6015 COLTON BLVD, OAKLAND CA 94611 |
Eric Fink | officer: Chief Human Resources Officer | C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080 |
Kim Smith-whitley | officer: See Remarks | C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 |
Alexis A. Thompson | director | C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 |
Brian Edwin Cathers | officer: Chief Scientific Officer | C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080 |
Lesley Ann Calhoun | officer: See Remarks | C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Mark L Perry | director | 176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941 |
Ted W Love | director, officer: See Remarks | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Tricia Borga Suvari | officer: Chief Legal Officer | 3172 PORTER DRIVE PALO ALTO CA 94034 |
Brown Willie L. Jr. | director | C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-10-2022
By Business Wire Business Wire • 08-31-2022
By PurpleRose PurpleRose • 08-08-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By PurpleRose PurpleRose • 08-03-2022
By PurpleRose PurpleRose • 08-09-2022
By PurpleRose PurpleRose • 07-13-2022
By PurpleRose PurpleRose • 07-15-2022
By PRNewswire PRNewswire • 08-08-2022
By PurpleRose PurpleRose • 07-29-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.